Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies
No abstract is available for this item.
|Date of creation:||2003|
|Date of revision:|
|Contact details of provider:|| Postal: |
Phone: +358 (0)9 609 900
Fax: +358 (0)9 601 753
Web page: http://www.etla.fi/
More information through EDIRC
|Order Information:|| Email: |
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Ismo Linnosmaa & Raine Hermans & Taru Hallinen, 2004. "Price-cost margin in the pharmaceutical industry," The European Journal of Health Economics, Springer, vol. 5(2), pages 122-128, May.
- Robert E. Hall, 2000.
"The stock market and capital accumulation,"
Federal Reserve Bank of San Francisco, issue Apr.
- Michael R. Darby & Lynne G. Zucker, 2002. "Going Public When You Can in Biotechnology," NBER Working Papers 8954, National Bureau of Economic Research, Inc.
When requesting a correction, please mention this item's handle: RePEc:rif:dpaper:856. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Kaija Hyvönen-Rajecki)
If references are entirely missing, you can add them using this form.